113 related articles for article (PubMed ID: 17242146)
1. Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives.
Stevens M; Pollicita M; Pannecouque C; Verbeken E; Tabarrini O; Cecchetti V; Aquaro S; Perno CF; Fravolini A; De Clercq E; Schols D; Balzarini J
Antimicrob Agents Chemother; 2007 Apr; 51(4):1407-13. PubMed ID: 17242146
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
[TBL] [Abstract][Full Text] [Related]
3. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones.
Tabarrini O; Massari S; Daelemans D; Stevens M; Manfroni G; Sabatini S; Balzarini J; Cecchetti V; Pannecouque C; Fravolini A
J Med Chem; 2008 Sep; 51(17):5454-8. PubMed ID: 18710207
[TBL] [Abstract][Full Text] [Related]
5. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
[TBL] [Abstract][Full Text] [Related]
6. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
Lapenta C; Spada M; Santini SM; Racca S; Dorigatti F; Poli G; Belardelli F; Alfano M
Int Immunol; 2005 Apr; 17(4):469-75. PubMed ID: 15746245
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
8. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H; Maeda K; Miyakawa T; Shibayama S; Matsuo M; Takaoka Y; Ito M; Koyanagi Y; Mitsuya H
J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide.
D'Cruz OJ; Uckun FM
Mol Hum Reprod; 2005 Oct; 11(10):767-77. PubMed ID: 16254003
[TBL] [Abstract][Full Text] [Related]
10. A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication.
Massari S; Daelemans D; Barreca ML; Knezevich A; Sabatini S; Cecchetti V; Marcello A; Pannecouque C; Tabarrini O
J Med Chem; 2010 Jan; 53(2):641-8. PubMed ID: 19958026
[TBL] [Abstract][Full Text] [Related]
11. HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.
Taggart BR; Harrington P; Hollingshead M
Antiviral Res; 2004 Jul; 63(1):1-6. PubMed ID: 15196814
[TBL] [Abstract][Full Text] [Related]
12. Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity.
He QQ; Gu SX; Liu J; Wu HQ; Zhang X; Yang LM; Zheng YT; Chen FE
Bioorg Med Chem; 2011 Aug; 19(16):5039-45. PubMed ID: 21763149
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells.
Wang EJ; Pettoello-Mantovani M; Anderson CM; Osiecki K; Moskowitz D; Goldstein H
J Infect Dis; 2002 Nov; 186(10):1412-21. PubMed ID: 12404156
[TBL] [Abstract][Full Text] [Related]
14. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
[TBL] [Abstract][Full Text] [Related]
15. Studies of anti-HIV transcription inhibitor quinolones: identification of potent N1-vinyl derivatives.
Tabarrini O; Massari S; Daelemans D; Meschini F; Manfroni G; Bottega L; Gatto B; Palumbo M; Pannecouque C; Cecchetti V
ChemMedChem; 2010 Nov; 5(11):1880-92. PubMed ID: 20928882
[TBL] [Abstract][Full Text] [Related]
16. Polysulfated sialic acid derivatives as anti-human immunodeficiency virus.
Terada M; Fujita S; Suda I; Mastico R
Biomed Pharmacother; 2005 Sep; 59(8):423-9. PubMed ID: 16143490
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
[TBL] [Abstract][Full Text] [Related]
19. Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation.
Stevens M; Balzarini J; Tabarrini O; Andrei G; Snoeck R; Cecchetti V; Fravolini A; De Clercq E; Pannecouque C
J Antimicrob Chemother; 2005 Nov; 56(5):847-55. PubMed ID: 16150861
[TBL] [Abstract][Full Text] [Related]
20. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
